Zacks Research Downgrades Theravance Biopharma (NASDAQ:TBPH) to Hold

Posted by Geri Gentry on Jun 10th, 2026

Theravance Biopharma (NASDAQ:TBPH – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Several other research analysts also recently commented on TBPH. Weiss Ratings downgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 27th. BTIG Research reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. B. Riley Financial raised their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Tuesday, April 7th. Finally, HC Wainwright raised their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.83.

Read Our Latest Report on TBPH

Theravance Biopharma Stock Up 1.2%

Theravance Biopharma stock opened at $16.49 on Monday. Theravance Biopharma has a twelve month low of $10.42 and a twelve month high of $21.03. The firm has a 50 day moving average price of $16.42 and a 200-day moving average price of $17.50. The company has a market capitalization of $850.06 million, a P/E ratio of 7.50 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last released its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The company had revenue of $17.70 million for the quarter. Equities analysts expect that Theravance Biopharma will post 1.58 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.65% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

A number of large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares in the last quarter. Creative Planning boosted its stake in shares of Theravance Biopharma by 6.7% during the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock valued at $196,000 after purchasing an additional 842 shares in the last quarter. State of Wyoming boosted its stake in shares of Theravance Biopharma by 5.7% during the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after purchasing an additional 1,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Theravance Biopharma by 6.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock valued at $174,000 after purchasing an additional 1,020 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

(Get Free Report)

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.